{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:14:08Z","timestamp":1761920048686,"version":"build-2065373602"},"reference-count":37,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2015,9,10]],"date-time":"2015-09-10T00:00:00Z","timestamp":1441843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Fingolimod, an oral sphingosine 1-phosphate (S1P) receptor modulator, is approved for the treatment of relapsing forms of multiple sclerosis (MS). The interference with S1P signaling leads to retention particularly of chemokine receptor-7 (CCR7) expressing T cells in lymph nodes. The immunological basis of varicella zoster virus (VZV) infections during fingolimod treatment is unclear. Here, we studied the dynamics of systemic and intrathecal immune responses associated with symptomatic VZV reactivation including cessation of fingolimod and initiation of antiviral therapy. Key features in peripheral blood were an about two-fold increase of VZV-specific IgG at diagnosis of VZV reactivation as compared to the previous months, a relative enrichment of effector CD4+ T cells (36% versus mean 12% in controls), and an accelerated reconstitution of absolute lymphocytes counts including a normalized CD4+\/CD8+ ratio and reappearance of CCR7+ T cells. In cerebrospinal fluid (CSF) the lymphocytic pleocytosis and CD4+\/CD8+ ratios at diagnosis of reactivation and after nine days of fingolimod discontinuation remained unchanged. During this time CCR7+ T cells were not observed  in CSF. Further research into fingolimod-associated VZV reactivation and immune reconstitution is mandatory to prevent morbidity and mortality associated with this potentially life-threatening condition.<\/jats:p>","DOI":"10.3390\/ijms160921832","type":"journal-article","created":{"date-parts":[[2015,9,11]],"date-time":"2015-09-11T02:50:46Z","timestamp":1441939846000},"page":"21832-21845","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Adaptive Immune Responses in a Multiple Sclerosis Patient with Acute Varicella-Zoster Virus Reactivation during Treatment with Fingolimod"],"prefix":"10.3390","volume":"16","author":[{"given":"Andrea","family":"Harrer","sequence":"first","affiliation":[{"name":"Department of Neurology, Christian Doppler Medical Center, Paracelsus Medical University,  5020 Salzburg, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Wipfler","sequence":"additional","affiliation":[{"name":"Department of Neurology, Christian Doppler Medical Center, Paracelsus Medical University,  5020 Salzburg, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Pilz","sequence":"additional","affiliation":[{"name":"Department of Neurology, Christian Doppler Medical Center, Paracelsus Medical University,  5020 Salzburg, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrin","family":"Oppermann","sequence":"additional","affiliation":[{"name":"Department of Neurology, Christian Doppler Medical Center, Paracelsus Medical University,  5020 Salzburg, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Haschke-Becher","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Paracelsus Medical University, 5020 Salzburg, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahrzad","family":"Afazel","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Paracelsus Medical University, 5020 Salzburg, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rg","family":"Kraus","sequence":"additional","affiliation":[{"name":"Department of Neurology, A.\u00f6. Krankenhaus Zell am See, Teaching Hospital of the Paracelsus Medical University, 5700 Zell am See, Austria"},{"name":"Research Institute of Neurointervention, Paracelsus Medical University, 5020 Salzburg, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugen","family":"Trinka","sequence":"additional","affiliation":[{"name":"Department of Neurology, Christian Doppler Medical Center, Paracelsus Medical University,  5020 Salzburg, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johann","family":"Sellner","sequence":"additional","affiliation":[{"name":"Department of Neurology, Christian Doppler Medical Center, Paracelsus Medical University,  5020 Salzburg, Austria"},{"name":"Department of Neurology, Klinikum rechts der Isar, Technische Universit\u00e4t,  81675 M\u00fcnchen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2015,9,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3810\/pgm.2013.09.2703","article-title":"Herpes zoster: Diagnostic, therapeutic, and preventive approaches","volume":"125","author":"Bader","year":"2013","journal-title":"Postgrad. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1212\/CPJ.0b013e31828d9f92","article-title":"The challenging patient with varicella-zoster virus disease","volume":"3","author":"Nagel","year":"2013","journal-title":"Neurol. Clin. Pract."},{"key":"ref_3","first-page":"341","article-title":"VZV T cell-mediated immunity","volume":"342","author":"Weinberg","year":"2010","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/j.1476-5381.2009.00451.x","article-title":"FTY720 (fingolimod) in Multiple Sclerosis: Therapeutic effects in the immune and the central nervous system","volume":"158","author":"Brinkmann","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1212\/01.wnl.0000327609.57688.ea","article-title":"FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis","volume":"71","author":"Mehling","year":"2008","journal-title":"Neurology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","article-title":"Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis","volume":"362","author":"Cohen","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1212\/WNL.0b013e3182735d24","article-title":"Multiple sclerosis rebound following herpes zoster infection and suspension of fingolimod","volume":"79","author":"Gross","year":"2012","journal-title":"Neurology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/WNL.0000000000001109","article-title":"VZV encephalitis that developed in an immunized patient during fingolimod therapy","volume":"84","author":"Issa","year":"2015","journal-title":"Neurology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1212\/01.wnl.0000432547.27815.74","article-title":"Varicella-zoster virus encephalitis and vasculopathy in a patient treated with fingolimod","volume":"81","author":"Ratchford","year":"2013","journal-title":"Neurology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/jamaneurol.2014.3065","article-title":"Varicella-zoster virus infections in patients treated with fingolimod: Risk assessment and consensus recommendations for management","volume":"72","author":"Arvin","year":"2015","journal-title":"JAMA Neurol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann. Neurol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1212\/WNL.0b013e31829a3311","article-title":"T-cell response against varicella-zoster virus in fingolimod-treated MS patients","volume":"81","author":"Ricklin","year":"2013","journal-title":"Neurology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1086\/315347","article-title":"Frequencies of memory T cells specific for varicella-zoster virus, herpes simplex virus, and cytomegalovirus by intracellular detection of cytokine expression","volume":"181","author":"Asanuma","year":"2000","journal-title":"J. Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1001\/jamaneurol.2014.3390","article-title":"Fingolimod and risk of varicella-zoster virus infection: Back to the future with an old infection and a new drug","volume":"72","author":"Tyler","year":"2015","journal-title":"JAMA Neurol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1097\/01.jnen.0000235852.92963.bf","article-title":"Latency of alpha-herpes viruses is accompanied by a chronic inflammation in human trigeminal ganglia but not in dorsal root ganglia","volume":"65","author":"Hufner","year":"2006","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/35065118","article-title":"Skewed maturation of memory HIV-specific CD8 T lymphocytes","volume":"410","author":"Champagne","year":"2001","journal-title":"Nature"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/44385","article-title":"Two subsets of memory T lymphocytes with distinct homing potentials and effector functions","volume":"401","author":"Sallusto","year":"1999","journal-title":"Nature"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jneuroim.2014.03.007","article-title":"FTY720 impairs CD8 T-cell function independently of the sphingosine-1-phosphate pathway","volume":"270","author":"Ntranos","year":"2014","journal-title":"J. Neuroimmunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1093\/infdis\/jiu500","article-title":"Altered phenotype and functionality of varicella zoster virus-specific cellular immunity in individuals with active infection","volume":"211","author":"Schub","year":"2015","journal-title":"J. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/j.1365-2249.2008.03633.x","article-title":"Varicella zoster virus glycoprotein E-specific CD4+ T cells show evidence of recent activation and effector differentiation, consistent with frequent exposure to replicative cycle antigens in healthy immune donors","volume":"152","author":"Malavige","year":"2008","journal-title":"Clin. Exp. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1177\/0091270011427908","article-title":"Pharmacodynamic effects of steady-state fingolimod on antibody response in healthy volunteers: A 4-week, randomized, placebo-controlled, parallel-group, multiple-dose study","volume":"52","author":"Boulton","year":"2012","journal-title":"J. Clin. Pharmacol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1212\/WNL.0000000000001302","article-title":"Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis","volume":"84","author":"Kappos","year":"2015","journal-title":"Neurology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2165\/11596550-000000000-00000","article-title":"Clinical pharmacokinetics of fingolimod","volume":"51","author":"David","year":"2012","journal-title":"Clin. Pharmacokinet."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1124\/dmd.110.035378","article-title":"CYP4F enzymes are responsible for the elimination of fingolimod (FTY720), a novel treatment of relapsing multiple sclerosis","volume":"39","author":"Jin","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1124\/dmd.110.035907","article-title":"Absorption and disposition of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in healthy volunteers: A case of xenobiotic biotransformation following endogenous metabolic pathways","volume":"39","author":"Zollinger","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"ref_27","unstructured":"U.S. Food and Drug Administration, Available online: http:\/\/www.fda.gov\/Drugs."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1126\/science.1144830","article-title":"Regulation of homeostatic chemokine expression and cell trafficking during immune responses","volume":"317","author":"Mueller","year":"2007","journal-title":"Science"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1212\/WNL.0b013e3182143564","article-title":"Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS","volume":"76","author":"Kowarik","year":"2011","journal-title":"Neurology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/INF.0b013e3181f6f78a","article-title":"Meningoencephalitis caused by varicella-zoster virus reactivation in a child with dominant partial interferon-\u03b3 receptor-1 deficiency","volume":"30","author":"Roesler","year":"2011","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1073\/pnas.1415875112","article-title":"B-cell repertoire responses to varicella-zoster vaccination in human identical twins","volume":"112","author":"Wang","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1007\/s13365-011-0066-x","article-title":"Investigation of varicella-zoster virus neurotropism and neurovirulence using SCID mouse-human DRG xenografts","volume":"17","author":"Zerboni","year":"2011","journal-title":"J. Neurovirol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1007\/s11481-013-9465-5","article-title":"Fingolimod modulates peripheral effector and regulatory T cells in MS patients","volume":"8","author":"Serpero","year":"2013","journal-title":"J. Neuroimmune. Pharmacol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/ana.22352","article-title":"Antigen-specific adaptive immune responses in fingolimod-treated multiple sclerosis patients","volume":"69","author":"Mehling","year":"2011","journal-title":"Ann. Neurol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"7973","DOI":"10.4049\/jimmunol.175.12.7973","article-title":"The sphingosine 1-phosphate receptor agonist FTY720 differentially affects the sequestration of CD4+\/CD25+ T-regulatory cells and enhances their functional activity","volume":"175","author":"Sawicka","year":"2005","journal-title":"J. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s11481-013-9510-4","article-title":"Recurrent varicella following steroids and fingolimod in a multiple sclerosis patient","volume":"8","author":"Ferraro","year":"2013","journal-title":"J. Neuroimmune. Pharmacol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1128\/CMR.17.4.903-925.2004","article-title":"Molecular methods for diagnosis of viral encephalitis","volume":"17","author":"Debiasi","year":"2004","journal-title":"Clin. Microbiol. Rev."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/16\/9\/21832\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T20:48:17Z","timestamp":1760215697000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/16\/9\/21832"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,10]]},"references-count":37,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2015,9]]}},"alternative-id":["ijms160921832"],"URL":"https:\/\/doi.org\/10.3390\/ijms160921832","relation":{},"ISSN":["1422-0067"],"issn-type":[{"type":"electronic","value":"1422-0067"}],"subject":[],"published":{"date-parts":[[2015,9,10]]}}}